ClinicalTrials.gg
Enrolling by invitationNCT07670702EMPOWER-EXTUpdated Sep 4, 2026

An Evaluation of the Long-Term Safety and Efficacy of TSND-201 for the Treatment of PTSD

A Phase 3 interventional study of TSND-201 in Post Traumatic Stress Disorder, sponsored by Transcend Therapeutics. Enrolling by invitation at 17 sites in United States. Per ClinicalTrials.gov, last updated 2026-09-04.

Sponsored by Transcend Therapeutics (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
300
Allocation
Not applicable
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies in Stress Disorders, Post-Traumatic by Otsuka Holdings Co., Ltd. — 3 open to participants now, 3 under way, 3 of them phase 3. Stress Disorders, Post-Traumatic · Otsuka Holdings Co., Ltd..

Planned enrollment
4th of 11
300 · median 300
Started
2026
with 2 others
Phase 3
5 of 11
3 open now
Registered
10th of 11
by date

Among the 11 studies in Stress Disorders, Post-Traumatic by Otsuka Holdings Co., Ltd., this one is the 4th largest by planned enrollment, is one of 3 that started in 2026, is one of 5 in phase 3, and was the 10th registered.

Stress Disorders, Post-Traumatic

2,687 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 603 are open to participants now.

Browse Stress Disorders, Post-Traumatic studies →

Open to participants now

3 of the 11 studies in Stress Disorders, Post-Traumatic by Otsuka Holdings Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 417 Stress Disorders, Post-Traumatic studies recruiting now, 187 (45%) set no upper age limit and 204 (49%) stop at 75 or younger; 63 take children under 18; 89 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Stress Disorders, Post-Traumatic by Otsuka Holdings Co., Ltd., or all of them as a file.
02

Study summary

This study is evaluating the long-term safety and efficacy of TSND-201 in adults with PTSD. Participants that have completed a double-blind clinical trial with TNSD-201 for PTSD will be invited to participate in this open-label extension trial.

Each participant will be able to receive up to three Treatment Courses over the duration of the study (up to 48 weeks). Each Treatment Course includes 4 dosing sessions, spaced one week apart.

03

Conditions studied

  • Post Traumatic Stress Disorder

Keywords

  • PTSD
  • EMPOWER-EXT
  • Transcend Therapeutics
  • TSND-201
  • Neuroplastogen
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Completion of a double-blind Transcend-sponsored clinical trial with TSND-201 (e.g., TSND201-PTSD-301) and considered in good standing with the study site.
  • Proficient in communication (verbal and reading) to complete interviews and written questionnaires.
  • Agree to not participate in any other interventional clinical trials for the duration of this study.

Exclusion criteria

Exclusion Criteria:

  • Experienced an intolerable side effect following dosing with TSND-201 in the prior study.
  • Had significant deviation(s)/non-compliance in parent study in the opinion of the Investigator which would deem them unsuitable for participation.
  • Change or development of any physical or psychological finding that would make participant unsuitable for study.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    TSND-201

    Drug: TSND-201

Interventions

  • TSND-201 capsules, given orally; where a course of treatment includes dosing with TSND-201 once a week for four consecutive weeks

06

What researchers measure

Primary outcomes

  1. Change from Baseline in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) Total Severity Score

    CAPS-5 is a structured interview designed to assess PTSD symptoms severity. The total severity score ranges from 0 to 80, with a higher score indicating more severe symptoms.

    Time frame: Up to 48 weeks

07

Study locations

17 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Dec 2028, 30 months after the start.

Of 34 phase 3 interventional studies under Stress Disorders, Post-Traumatic, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 54. This study's planned 30 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 19, 2026
First posted
Jun 26, 2026
StartActual
Jun 22, 2026
Primary completionEst.
Dec 2028
CompletionEst.
Jan 2029
Last update
Sep 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07670702
Responsible party
Sponsor
First posted
Jun 26, 2026
Start date
Jun 22, 2026
Primary completion
Dec 2028 (estimated)
Completion
Jan 2029 (estimated)
Last update
Sep 4, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TSND-201

Start the discussion